- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01490489
EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction (EGEVE)
EG-VEGF (Endocrine Gland-derived Vascular Endothelial Growth Factor) in Normal and Pathological Pregnancies: Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Successful human placentation depends on adequate transformation of the uteroplacental vasculature by extravillous trophoblast (EVT) following proliferation, migration, and invasion of these cells into the maternal decidua. This process of vascular remodelling rises to a peak by the end of the first trimester and declines rapidly thereafter. Poor invasion can lead to the development of pathological condition such as Pre-eclampsia (PE) and intrauterine growth restriction (IUGR). PE affects 5-6 % of pregnancies in France and causes the death of ten or so women per year. Our research project is dedicated to the comprehension of the mechanisms underlying the development of PE and to the search of gold prognostic marker of this pathology. We were particularly interested in the study of the new angiogenic factor, EG-VEGF, recently reported as new factor specific to endocrine glands including the placenta. In recent results obtained by our team, we have shown that i) placental EG-VEGF showed a peak of expression just before the establishment of the foeto-maternal circulation ii) EG-VEGF receptors, PKR1 and PKR2 were also expressed during the first trimester of pregnancy and iii) EG-VEGF expression and that of its receptor PKR1 were up-regulated by hypoxia. In our last publication "under press in JCMM" we have shown that EG-VEGF inhibits EVT migration and invasion. More importantly, we have succeeded to measure EG-VEGF circulating levels in non pregnant and in pregnant women at the three trimesters of pregnancy and showed that its highest levels (5 times the non pregnant levels) were found during the first trimester of pregnancy with a significant decrease thereafter. Furthermore, on a cohort of 19 PE patient and 21 age matched controls, we have observed a significant increase in EG-VEGF levels in the PE group. Therefore we hypothesize that EG-VEGF could play an important role in human placentation and that a persistence in its expression over the first trimester of pregnancy may contribute to the development of PE.
Based on the Doppler analysis method for the assessment of uterine artery transformation by the end of 1st trimester, we propose to search for a correlation between the circulating levels of the new angiogenic factor EG-VEGF in the sera of pregnant woman between 14 to 18 WG, and the development of PE and/or IUGR. Doppler ultrasonography is a predictive method of the pregnancy outcome at the time of the development of the disease (1st to 2nd trimester), before threatening symptoms launch (end of the 2nd to the 3rd trimester). In normal pregnancy, impedance to flow in the uterine arteries decreases with gestation as result of trophoblastic invasion of the spiral arteries and their conversion into low-resistance vessels by the end of first trimester of pregnancy. Therefore, the present study will also allow the search for a negative correlation between the level of uterine artery transformation and the level of EG-VEGF. The study will be conducted in collaboration with the Clinical centre of the Grenoble CHU Hospital (Dr JL. Cracowski). In this study we plan to include 500 pregnant pregnant women. Patients will be recruited at the time of their first ultrasonography between 11 and 13 WG and included in the study between 14 and 18 WG. For each patient a blood sample will be taken for the measurement of circulating EG-VEGF and Doppler analysis for uterine artery transformation will be performed. These results will provide information concerning the potential prognostic value of seric concentrations of EG-VEGF for PE and/or IUGR and will allow checking whether plasma levels of EG-VEGF at 14-18 weeks of gestation could be proposed as prognostic marker for preeclampsia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Isere
-
Grenoble, Isere, France, 38043
- Clinical investigation center of the Grenoble University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women older than 17 years old
- All pregnant patients enrolled before 14 SG and with singleton, irrespectively of their parity
- Pregnant woman living in the Grenoble area
- Women accepting, the participation to the study.
Exclusion Criteria:
- Inability to understand the project
- Persons deprived of their liberty by judicial or administrative decisions
- Person under legal protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Pregnent women with blood sample
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of the circulating levels of EG-VEGF in the sera of pregnant woman between 14 and 18 WG
Time Frame: Between 14 and 18 weeks of gestation
|
Measure the circulating levels of the new angiogenic factor EG-VEGF in the sera of pregnant woman between 14 and 18 WG to determine whether EG-VEGF could represent a prognostic marker for the development of PE and/or IUGR
|
Between 14 and 18 weeks of gestation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between the level of uterine artery transformation and the level of EG-VEGF.
Time Frame: Between 14 and 18 week of gestation
|
Correlation between the level of EG-VEGF and the level of uterine artery transformation evaluated by Doppler ultrasound.
|
Between 14 and 18 week of gestation
|
Measure the circulating levels of other pro and/or anti-angiogenic factors
Time Frame: Between 14 and 18 week of gestation
|
Measure the circulating levels of other pro and/or anti-angiogenic factors that could represent alternative biomarkers in the development of placental pathologies of vascular origin.
As candidates, we will measure the soluble receptor of VEGF (s-flt) and Bone morphogenetic protein-9 (BMP9)
|
Between 14 and 18 week of gestation
|
Measure the circulating levels of the new angiogenic factor EG-VEGF
Time Frame: Between 14 and 18 weeks of gestation
|
Measure the circulating levels of the new angiogenic factor EG-VEGF in the sera of pregnant woman between 14 and 18 WG to determine whether EG-VEGF could represent a prognostic marker for the development of PE.
|
Between 14 and 18 weeks of gestation
|
Measure the circulating levels of the new angiogenic factor EG-VEGF in the sera
Time Frame: Between 14 and 18 weeks of gestation
|
Measure the circulating levels of the new angiogenic factor EG-VEGF in the sera of pregnant woman between 14 and 18 WG to determine whether EG-VEGF could represent a prognostic marker for the development of IUGR
|
Between 14 and 18 weeks of gestation
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pascale Hoffmann, MD/PHD, University Hospital, Grenoble
- Study Director: Nadia ALFAIDI, PHD, inserm U878
Publications and helpful links
General Publications
- Hoffmann P, Feige JJ, Alfaidy N. Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. Placenta. 2007 Oct;28(10):1049-58. doi: 10.1016/j.placenta.2007.03.008. Epub 2007 May 25.
- Hoffmann P, Feige JJ, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology. 2006 Apr;147(4):1675-84. doi: 10.1210/en.2005-0912. Epub 2005 Dec 29.
- Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazouni C, Feige JJ, Alfaidy N. Role of EG-VEGF in human placentation: Physiological and pathological implications. J Cell Mol Med. 2009 Aug;13(8B):2224-2235. doi: 10.1111/j.1582-4934.2008.00554.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C09-43
- 2009-A01304-53 (Registry Identifier: IDRCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre-eclampsia
-
Assiut UniversityNot yet recruitingPre-eclampsia Aggravated | Pre-Eclampsia; Complicating Pregnancy
-
University of WashingtonUniversity of Cape TownCompletedSevere Pre-eclampsia | Mild Pre-eclampsiaSouth Africa, United States
-
Dow University of Health SciencesCompletedPre-eclampsia | Hypertension, Pregnancy Induced | Hydralazine Adverse Reaction | Pre-eclampsia Superimposed Pre-existing HypertensionPakistan
-
William Marsh Rice UniversityUniversity of MalawiCompleted
-
Duke UniversityTerminated
-
William Marsh Rice UniversityCompletedPre EclampsiaUnited States
-
Oxford University Hospitals NHS TrustUniversity of CambridgeTerminated
-
Novartis PharmaceuticalsTerminatedPre-eclampsiaItaly, United States
-
Ain Shams UniversityCompleted
-
Nantes University HospitalCompleted
Clinical Trials on blood sample and doppler Ultrasound of uterine arteries
-
Cairo UniversityCompletedLeiden Factor V Deficiency,Preeclampsia | Doppler Examination | Palental Pathology
-
Fundación GinemedUniversity of Seville; Hospitales Universitarios Virgen del Rocío; Clínicas Ginemed and other collaboratorsNot yet recruitingPreeclampsia | Intrauterine Growth Restriction | Placental Disease
-
Second Affiliated Hospital of Wenzhou Medical UniversityNot yet recruiting
-
Uppsala UniversityRoche Pharma AG; Perkin Elmer Inc.; Thermo Fisher Scientific, IncActive, not recruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompletedAcute Kidney InjuryFrance
-
Universitaire Ziekenhuizen KU LeuvenAmsterdam UMC, location VUmc; Rennes University Hospital; Bichat HospitalRecruitingFibroid UterusBelgium, France, Netherlands
-
Cedars-Sinai Medical CenterCompletedEstrogen DeficiencyUnited States
-
National Institute of Diabetes and Digestive and...Cystic Fibrosis FoundationCompletedCystic Fibrosis | Pancreatic InsufficiencyUnited States, Canada
-
Charite University, Berlin, GermanyCompletedLeiomyoma | Laparoscopic MyomectomyGermany
-
University Medical Centre LjubljanaUniversity of LjubljanaCompletedEndometriosis